ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...
The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
Medtronic plc MDT recently commenced the enrolment for a prospective, multicenter, global, post-market study of its InterStim Micro neurostimulator — Evaluation of InterStim Micro System Performance ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback